SEC Info℠  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Intellipharmaceutics International Inc. – ‘20-F’ for 2/27/17 – ‘EX-16.1’

On:  Tuesday, 2/28/17, at 4:38pm ET   ·   For:  2/27/17   ·   Accession #:  1654954-17-1523   ·   File #:  0-53805

Previous ‘20-F’:  ‘20-F’ on 3/21/16 for 11/30/15   ·   Next:  ‘20-F’ on 3/1/18 for 2/28/18   ·   Latest:  ‘20-F/A’ on 2/6/24 for 11/30/22   ·   5 References:   

Find Words in Filings emoji
 		  in    Show  and   ↓Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 2/28/17  Intellipharmaceutics Int’l Inc.   20-F        2/27/17   91:8M                                     Blueprint/FA

Annual Report by a Foreign Non-Canadian Issuer   —   Form 20-F   —   Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 20-F        Annual Report by a Foreign Non-Canadian Issuer      HTML   1.42M 
 2: EX-4.72     Instrument Defining the Rights of Security Holders  HTML     26K 
 3: EX-4.73     Instrument Defining the Rights of Security Holders  HTML     26K 
 4: EX-4.74     Instrument Defining the Rights of Security Holders  HTML    176K 
                -- exhibit474                                                    
 5: EX-8.1      Opinion of Counsel re: Tax Matters                  HTML     22K 
 8: EX-13.1     Annual or Quarterly Report to Security Holders --   HTML     25K 
                exhibit131                                                       
 9: EX-13.2     Annual or Quarterly Report to Security Holders --   HTML     25K 
                exhibit132                                                       
 6: EX-12.1     Statement re: Computation of Ratios -- exhibit121   HTML     28K 
 7: EX-12.2     Statement re: Computation of Ratios -- exhibit122   HTML     28K 
10: EX-15.1     Letter re: Unaudited Interim Financial Info --      HTML     25K 
                exhibit151                                                       
11: EX-15.2     Letter re: Unaudited Interim Financial Info --      HTML     26K 
                exhibit152                                                       
12: EX-16.1     Letter re: Change in Certifying Accountant --       HTML     25K 
                exhibit161                                                       
19: R1          Document And Entity Information                     HTML     49K 
20: R2          Consolidated Balance Sheets                         HTML     93K 
21: R3          Consolidated Balance Sheets (Parenthetical)         HTML     29K 
22: R4          Consolidated Statements of Operations and           HTML     70K 
                Comprehensive Loss                                               
23: R5          Consolidated Statements of Shareholders' Equity     HTML     81K 
                (Deficiency)                                                     
24: R6          Consolidated Statements of Cash Flows               HTML    106K 
25: R7          Note 1 - Nature of Operations                       HTML     34K 
26: R8          Note 2 - Basis of Presentation                      HTML     29K 
27: R9          Note 3 - Significant Accounting Policies            HTML     77K 
28: R10         Note 4 - Accounts Receivable                        HTML     27K 
29: R11         Note 5 - Property and Equipment                     HTML     50K 
30: R12         Note 6 - Accrued Liabilities                        HTML     30K 
31: R13         Note 7 - Due to Related Parties                     HTML     41K 
32: R14         Note 8 - Employee Costs Payable                     HTML     28K 
33: R15         Note 9 - Lease Obligations                          HTML     35K 
34: R16         Note 10 - Capital Stock                             HTML     42K 
35: R17         Note 11 - Options                                   HTML    116K 
36: R18         Note 12 - Deferred Share Units                      HTML     35K 
37: R19         Note 13 - Restricted Share Units                    HTML     26K 
38: R20         Note 14 - Warrants                                  HTML     58K 
39: R21         Note 15 - Income Taxes                              HTML     73K 
40: R22         Note 16 - Contingencies                             HTML     27K 
41: R23         Note 17 - Financial Instruments                     HTML     86K 
42: R24         Note 18 - Segmented Information                     HTML     43K 
43: R25         Note 19 - Subsequent Event                          HTML     26K 
44: R26         Note 3 - Significant Accounting Policies            HTML    125K 
                (Policies)                                                       
45: R27         Note 3 - Significant Accounting Policies (Tables)   HTML     28K 
46: R28         Note 5 - Property and Equipment (Tables)            HTML     47K 
47: R29         Note 6 - Accrued Liabilities (Tables)               HTML     29K 
48: R30         Note 7 - Due to Related Parties (Tables)            HTML     29K 
49: R31         Note 9 - Lease Obligations (Tables)                 HTML     33K 
50: R32         Note 11 - Options (Tables)                          HTML    113K 
51: R33         Note 12 - Deferred Share Units (Tables)             HTML     33K 
52: R34         Note 14 - Warrants (Tables)                         HTML     54K 
53: R35         Note 15 - Income Taxes (Tables)                     HTML     71K 
54: R36         Note 17 - Financial Instruments (Tables)            HTML     84K 
55: R37         Note 18 - Segmented Information (Tables)            HTML     38K 
56: R38         Note 1 - Nature of Operations (Details)             HTML     31K 
57: R39         Note 3 - Significant Accounting Policies (Details)  HTML     30K 
58: R40         Note 3 - Significant Accounting Policies (Details   HTML     40K 
                1)                                                               
59: R41         Note 5 - Property and Equipment (Details)           HTML     26K 
60: R42         Note 5 - Property and Equipment (Details 1)         HTML     52K 
61: R43         Note 6 - Accrued Liabilities (Details) - Accrued    HTML     33K 
                Liabilities                                                      
62: R44         Note 7 - Due to Related Parties (Details)           HTML     49K 
63: R45         Note 7 - Due to Related Parties (Details 1)         HTML     26K 
64: R46         Note 8 - Employee Costs Payable (Details)           HTML     28K 
65: R47         Note 9 - Lease Obligations (Details)                HTML     45K 
66: R48         Note 10 - Capital Stock (Details)                   HTML     36K 
67: R49         Note 11 - Options (Details)                         HTML     40K 
68: R50         Note 11 - Options (Details 1)                       HTML     64K 
69: R51         Note 11 - Options (Details 2)                       HTML     69K 
70: R52         Note 11 - Options (Details 3)                       HTML     32K 
71: R53         Note 11 - Options (Details Narrative)               HTML     43K 
72: R54         Note 12 - Deferred Share Units (Details)            HTML     31K 
73: R55         Note 12 - Deferred Share Units (Details Narrative)  HTML     34K 
74: R56         Note 13 - Restricted Share Units (Details           HTML     27K 
                Narrative)                                                       
75: R57         Note 14 - Warrants (Details)                        HTML     49K 
76: R58         Note 14 - Warrants (Details 1)                      HTML     44K 
77: R59         Note 14 - Warrants (Details Narrative)              HTML     55K 
78: R60         Note 15 - Income Taxes (Details)                    HTML     57K 
79: R61         Note 15 - Income Taxes (Details 1)                  HTML     47K 
80: R62         Note 15 - Income Taxes (Details 2)                  HTML     54K 
81: R63         Note 15 - Income Taxes (Details Narrative)          HTML     36K 
82: R64         Note 17 - Financial Instruments (Details)           HTML     32K 
83: R65         Note 17 - Financial Instruments (Details 1)         HTML     28K 
84: R66         Note 17 - Financial Instruments (Details 2)         HTML     41K 
85: R67         Note 17 - Financial Instruments (Details 3)         HTML     52K 
86: R68         Note 17 - Financial Instruments (Details 4)         HTML     58K 
87: R69         Note 17 - Financial Instruments (Details            HTML     29K 
                Narrative)                                                       
88: R70         Note 18 - Segmented Information (Details)           HTML     38K 
90: XML         IDEA XML File -- Filing Summary                      XML    155K 
89: EXCEL       IDEA Workbook of Financial Reports                  XLSX     94K 
13: EX-101.INS  XBRL Instance -- ipci-20161130                       XML   1.50M 
15: EX-101.CAL  XBRL Calculations -- ipci-20161130_cal               XML    167K 
16: EX-101.DEF  XBRL Definitions -- ipci-20161130_def                XML    487K 
17: EX-101.LAB  XBRL Labels -- ipci-20161130_lab                     XML   1.06M 
18: EX-101.PRE  XBRL Presentations -- ipci-20161130_pre              XML    760K 
14: EX-101.SCH  XBRL Schema -- ipci-20161130                         XSD    224K 
91: ZIP         XBRL Zipped Folder -- 0001654954-17-001523-xbrl      Zip    147K

‘EX-16.1’   —   Letter re: Change in Certifying Accountant — exhibit161

This Exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]

 C:   C: 
  Blueprint  
  Exhibit 16.1
Deloitte LLP
Bay Adelaide East
22 Adelaide Street West
Suite 200
Toronto ON M5H 0A9
Canada
Tel: 416-601-6150
Fax: 416-601-6610
www.deloitte.ca
February 27, 2017
 
Private and confidential
Securities and Exchange Commission
100 F Street, N.E.
Washington, DC
U.S.A. 20549
 
 
 
 
We have read the Intellipharmaceutics International Inc.’s statements included under Item 16F of its annual report on Form 20-F for the year ended November 30, 2016 and agree with such statements, except that we have no basis on which to agree or disagree with the statements that the newly engaged auditors (a) were approved by the Audit Committee and the Board of Directors of the Company and (b) were not consulted regarding any of the matters or events set forth in the fifth paragraph therein.
 
Yours truly,
 
/s/ Deloitte LLP
 
Chartered Professional Accountants
Licensed Public Accountants
 

Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘20-F’ Filing    Date    Other Filings
Filed on:2/28/176-K
For Period end:2/27/176-K
11/30/166-K
 List all Filings 

5 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 2/06/24  Intellipharmaceutics Int’l Inc.   20-F/A     11/30/22  100:8.5M                                   Blueprint/FA
 6/14/23  Intellipharmaceutics Int’l Inc.   20-F       11/30/22  100:8.5M                                   Blueprint/FA
 5/09/22  Intellipharmaceutics Int’l Inc.   20-F/A     11/30/21  104:9.3M                                   Blueprint/FA
 4/01/22  Intellipharmaceutics Int’l Inc.   20-F       11/30/20  104:9.2M                                   Blueprint/FA
 3/31/21  Intellipharmaceutics Int’l Inc.   20-F       12/31/20   97:7.3M                                   Blueprint/FA
↑Top
Filing Submission 0001654954-17-001523   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)
Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
About — Privacy — Redactions — Help — Fri., May 17, 4:30:51.1pm ET